27493840|t|Evaluation of Pharmacokinetics, and Bioavailability of Higher Doses of Tocotrienols in Healthy Fed Humans
27493840|a|Tocotrienols has been known to lower serum lipid parameters below 500 mg/d, while increase lipid parameters at higher dose of 750 mg/d. δ-Tocotrienol has a novel inflammatory property of concentration-dependent inhibition and activation. Therefore, inhibition (anti-inflammatory) property of tocotrienols at low doses is useful for cardiovascular disease, whereas, activation (pro-inflammatory) property using high dose is found effective for treatments of various types of cancer. We have recently described plasma bioavailability of 125 mg/d, 250 mg/d and 500 mg/d doses of δ-tocotrienol in healthy fed subjects, which showed dose-dependent increases in area under the curve (AUC) and maximum concentration (Cmax). Hence, in the current study, higher doses of tocotrienols have used to analyze its effect on plasma pharmacokinetic parameters. To evaluate the safety and bioavailability of higher doses (750 mg and 1000 mg) of annatto -based tocotrienols in healthy fed subjects. All four isomers (α-, β-, γ-, δ-) of tocols (tocotrienols and tocopherols) present in the plasmas of subjects were quantified and analyzed for various pharmacokinetic parameters. An open-label, randomized study was performed to analyze pharmacokinetics and bioavailability of δ-tocotrienol in 6 healthy fed subjects. All subjects (3/ dose) were randomly assigned to one of each dose of 750 mg or 1000 mg. Blood samples were collected at 0, 1, 2, 4, 6, 8 h intervals and all isomers of α-, β-, γ-, δ-tocotrienols, and tocopherols in plasmas were quantified by HPLC. Oral administration of 750 and 1000 mg/d of tocotrienols resulted in dose-dependent increases in plasmas (ng/ml) AUC t0-t8 6621, 7450; AUC t0-∞ 8688, 9633; AUMC t0-∞ 52497, 57199; MRT 6.04, 5.93; Cmax 1444, 1592 (P<0.05), respectively, of δ-tocotrienol isomer. Moreover, both doses also resulted in plasmas Tmax 3.33-4 h; elimination half-life (t1/2 h) 2.74, 2.68; time of clearance (Cl-T, l/h) 0.086, 0.078; volume of distribution (Vd/f, mg/h) 0.34, 0.30; and elimination rate constant (ke; h(-1)) 0.25, 0.17, respectively of δ- tocotrienol isomer. Similar results of these parameters were reported for γ-tocotrienol, β- tocotrienol, α-tocotrienol, δ-tocopherol, γ-tocopherol, and β-tocopherol, except for α- tocopherol. This study has described pharmacokinetics using higher doses of 750 mg/d and 1000 mg/d of δ-tocotrienol. These results confirmed earlier findings that Tmax was 3-4 h for all isomers of tocotrienols and tocopherols except for α-tocopherol (6 h). These higher doses of tocotrienols were found safe in humans and may be useful for treatments of various types of cancer, diabetes, and Alzheimer's disease.
27493840	0	10	Evaluation	T058	UMLS:C0220825
27493840	14	30	Pharmacokinetics	T038	UMLS:C0031327
27493840	71	83	Tocotrienols	T103	UMLS:C0949647
27493840	99	105	Humans	T204	UMLS:C0086418
27493840	106	118	Tocotrienols	T103	UMLS:C0949647
27493840	137	165	lower serum lipid parameters	T038	UMLS:C0856969
27493840	188	213	increase lipid parameters	T033	UMLS:C0856968
27493840	242	255	δ-Tocotrienol	T103	UMLS:C0218003
27493840	398	410	tocotrienols	T103	UMLS:C0949647
27493840	438	460	cardiovascular disease	T038	UMLS:C0007222
27493840	549	559	treatments	T058	UMLS:C0087111
27493840	580	586	cancer	T038	UMLS:C0006826
27493840	615	621	plasma	T031	UMLS:C0032105
27493840	682	695	δ-tocotrienol	T103	UMLS:C0218003
27493840	711	719	subjects	T098	UMLS:C2349001
27493840	749	782	increases in area under the curve	T033	UMLS:C1708492
27493840	868	880	tocotrienols	T103	UMLS:C0949647
27493840	916	922	plasma	T031	UMLS:C0032105
27493840	923	949	pharmacokinetic parameters	T170	UMLS:C1705911
27493840	954	962	evaluate	T058	UMLS:C0220825
27493840	1034	1041	annatto	T103	UMLS:C0051928
27493840	1049	1061	tocotrienols	T103	UMLS:C0949647
27493840	1077	1085	subjects	T098	UMLS:C2349001
27493840	1124	1130	tocols	T103	UMLS:C0599549
27493840	1132	1144	tocotrienols	T103	UMLS:C0949647
27493840	1149	1160	tocopherols	T103	UMLS:C0087096
27493840	1177	1184	plasmas	T031	UMLS:C0032105
27493840	1188	1196	subjects	T098	UMLS:C2349001
27493840	1217	1225	analyzed	T062	UMLS:C0936012
27493840	1238	1264	pharmacokinetic parameters	T170	UMLS:C1705911
27493840	1269	1279	open-label	T062	UMLS:C1709323
27493840	1281	1297	randomized study	T062	UMLS:C2986910
27493840	1323	1339	pharmacokinetics	T038	UMLS:C0031327
27493840	1363	1376	δ-tocotrienol	T103	UMLS:C0218003
27493840	1394	1402	subjects	T098	UMLS:C2349001
27493840	1408	1416	subjects	T098	UMLS:C2349001
27493840	1492	1505	Blood samples	T031	UMLS:C0178913
27493840	1572	1574	α-	T103	UMLS:C0217873
27493840	1576	1578	β-	T103	UMLS:C0217992
27493840	1580	1582	γ-	T103	UMLS:C0206999
27493840	1584	1598	δ-tocotrienols	T103	UMLS:C0218003
27493840	1604	1615	tocopherols	T103	UMLS:C0087096
27493840	1619	1626	plasmas	T031	UMLS:C0032105
27493840	1646	1650	HPLC	T058	UMLS:C0008562
27493840	1652	1671	Oral administration	T058	UMLS:C0001563
27493840	1696	1708	tocotrienols	T103	UMLS:C0949647
27493840	1749	1756	plasmas	T031	UMLS:C0032105
27493840	1891	1911	δ-tocotrienol isomer	T103	UMLS:C0218003
27493840	1951	1958	plasmas	T031	UMLS:C0032105
27493840	2179	2200	δ- tocotrienol isomer	T103	UMLS:C0218003
27493840	2227	2237	parameters	T033	UMLS:C0449381
27493840	2243	2251	reported	T058	UMLS:C0700287
27493840	2256	2269	γ-tocotrienol	T103	UMLS:C0206999
27493840	2271	2285	β- tocotrienol	T103	UMLS:C0217992
27493840	2287	2300	α-tocotrienol	T103	UMLS:C0217873
27493840	2302	2314	δ-tocopherol	T103	UMLS:C0304915
27493840	2316	2328	γ-tocopherol	T103	UMLS:C0017054
27493840	2334	2346	β-tocopherol	T103	UMLS:C0005287
27493840	2359	2372	α- tocopherol	T103	UMLS:C0969677
27493840	2399	2415	pharmacokinetics	T038	UMLS:C0031327
27493840	2464	2477	δ-tocotrienol	T103	UMLS:C0218003
27493840	2559	2571	tocotrienols	T103	UMLS:C0949647
27493840	2576	2587	tocopherols	T103	UMLS:C0087096
27493840	2599	2611	α-tocopherol	T103	UMLS:C0969677
27493840	2641	2653	tocotrienols	T103	UMLS:C0949647
27493840	2673	2679	humans	T204	UMLS:C0086418
27493840	2702	2712	treatments	T058	UMLS:C0087111
27493840	2733	2739	cancer	T038	UMLS:C0006826
27493840	2741	2749	diabetes	T038	UMLS:C0011847
27493840	2755	2774	Alzheimer's disease	T038	UMLS:C0002395